Maite Gorostegui Obanos
Investigador
Research group
Last Publications
- Chantada L, Gorostegui M, Lowe J, Ranasinghe N, Villegas L, Geel J, Howard S, Bouffet E, Chantada G, Challinor J and Cappellano A SIOP pediatric oncology services Global Mapping Program: Latin American data collection PEDIATRIC BLOOD & CANCER . 71(2): .
- Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes Cancers . 15(19): .
- Varo A, Castañeda-Heredia A, Chamorro S, Muñoz JP, Gorostegui M, Celma MS, Lopez S, Simao M, Pérez-Jaume S and Mora J Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab Frontiers in oncology . 13: 1164949-1164949.
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.